On Tuesday, Shares of Signal Genetics, Inc. (NASDAQ:SGNL), surged 47.97% to $2.19.
Signal Genetics, declared the signing of a Master Service Agreement (MSA) with a leading pharmaceutical company. Under the MSA, Signal’s proprietary MyPRS(R) genetic test will be run across multiple clinical trials in connection with the development of novel treatments for patients with multiple myeloma.
Signal and the pharmaceutical company have triggered the first of four studies as part of the MSA. Under the agreement, MyPRS(R) will assist inform patterns of response to novel therapy regimens with the aim of enabling physicians to better manage multiple myeloma patients based on their specific genetic profile.
Signal Genetics, Inc., a commercial stage molecular genetic diagnostic company, focuses on providing diagnostic services that assist physicians in decision making for the care of patients suffering from cancer.
Shares of Southwest Airlines Co. (NYSE:LUV), declined -0.27% to $33.09, during its last trading session.
Southwest Airlines, is giving Customers a first look at its early 2016 flight plan by extending it from Jan. 6 through Mar. 8, 2016, and is offering special pricing for new nonstop service connecting these longtime Southwest cities:
Starting Jan. 6, 2016, fly Southwest Airlines nonstop between:
- Burbank and San Francisco, three times daily, for as low as $49 one-way.
- Sacramento and Boise, once daily, for as low as $49 one-way.
- Indianapolis and Chicago (Midway), twice daily, for as low as $49 one-way.
- Little Rock and St. Louis, twice daily, for as low as $49 one-way.
Customers can take advantage of these fares today through Friday, July 3, 2015, 11:59 p.m. in the respective time zone of the originating city. Fares are now accessible for travel on nonstop flights every day except Fridays and Sundays starting Jan. 6 through Mar. 8, 2016 (check fare rules below for restrictions and exclusions).
Southwest Airlines Co. operates passenger airlines that provide planned air transportation services in the United States and near-international markets. As of December 31, 2014, it operated 665 Boeing 737 aircraft; and had 12 Boeing 717 aircraft.
Finally, Bristol-Myers Squibb Company (NYSE:BMY), ended its last trade with 0.86% gain, and closed at $66.17.
Alexandria Real Estate Equities, Inc., the largest and leading REIT uniquely focused on collaborative science campuses in urban innovation clusters, declared that Bristol-Myers Squibb (BMY), a global biopharmaceutical company, will establish a state-of-the-art research and development center at the Alexandria Center® at Kendall Square (ACKS) in the heart of the Cambridge Kendall Square innovation cluster. As the anchor tenant in Alexandria’s newest ground-up development at 100 Binney Street, Bristol-Myers Squibb will lease 208,000 rentable square feet (RSF) in a world-class, highly sustainable office/laboratory facility that has a total of 431,500 RSF. The project will start construction in July 2015 and is predictable to be delivered in the fourth quarter of 2017.
The decision by Bristol-Myers Squibb to locate its state-of-the-art research facility in the Cambridge Kendall Square innovation cluster affirms Alexandria Center at Kendall Square’s reputation as one of the world’s most desirable locations for life science recruitment, innovation, and collaboration.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
